NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Tuesday that its second quarter revenues dropped 37 percent year over year.

For the three months ended June 30, the San Diego-based liquid biopsy firm saw $822,238 in revenues compared to $1.3 million a year ago.

According to the company, the drop resulted in part from a change in commercial revenue recognition to a method based on accruals from one based on cash. Based on accruals only, the firm's revenues for Q2 2017 would have been only $1.1 million, Biocept said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.